SY 161-P5

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameSY 161-P5
Drug Alias NamePEG-staphylokinasePEG-SakSTARPEG-SakPEGylated recombinant staphylokinase variant
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionPlasminogen stimulants
TargetsPlasminogen
Therapy Area/IndicationsMyocardial Infarction
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Leuven
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsMyocardial Infarction

Other Information

ATC CodeN/A
Related LinksN/A